Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $213 million, representing a 20% year-over-year growth and a 21% growth in surgical revenue [3][6] - For the full year 2025, total revenue reached $764 million, a $153 million increase year-over-year, equating to a 25% total revenue growth [4][16] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a margin of 16% [15][24] - The full year Adjusted EBITDA was $93 million, approximately 12% of sales, marking a significant improvement of $63 million year-over-year [17][24] Business Line Data and Key Metrics Changes - Surgical revenue in Q4 was $190 million, up 21% year-over-year, while EOS revenue was $23 million, up 14% year-over-year [6][8] - For the full year, surgical revenue totaled $687 million, a 26% increase compared to 2024, driven by a 22% growth in procedural volume [16][17] - EOS revenue for the full year was $77 million, reflecting a 15% year-over-year growth [16] Market Data and Key Metrics Changes - U.S. revenue per case increased by 1.4%, with lateral and cervical procedures both up 6% [7] - Same-store sales in the U.S. grew 20% year-over-year, indicating strong growth in established territories [8] Company Strategy and Development Direction - The company is focused on creating clinical distinction through proceduralization, particularly in lateral surgery, which is seen as a growth engine [26][29] - ATEC is expanding its sales force and enhancing its product offerings, including the introduction of advanced technologies like the Valence platform for intraoperative navigation [27][28] - The company aims to leverage its unique ecosystem to address complex pathologies in spine surgery, enhancing surgeon confidence and patient outcomes [30][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of top-line growth, driven by increasing surgeon adoption and procedural volume [9][19] - The outlook for 2026 anticipates revenue growth of 17% to approximately $890 million, with Adjusted EBITDA guidance increased to $134 million [19][24] - The company is positioned for long-term profitable growth, focusing on expanding its infrastructure and integrating data into surgical experiences [38][39] Other Important Information - The company ended Q4 with $161 million in cash and had access to an additional $60 million in undrawn credit, totaling $221 million in available cash [18] - Free cash flow for Q4 was $8 million, marking the first full year of positive free cash flow for the company [18][19] Q&A Session Summary Question: Concerns about share trading post-earnings - Management confirmed that Q4 results were in line with expectations, with EBITDA exceeding consensus by 10% and 2026 revenue guidance reaffirmed [44][45] Question: Cadence for 2026 revenue and EBITDA - Management indicated that Q1 revenue is expected to follow a similar seasonal pattern as 2025, with Q1 contributing about 22.1% of sales [47][48] Question: Attracting sales talent - Management stated that the hiring process is going well, with strong demand for the company's portfolio from both surgeons and sales personnel [53]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $213 million, representing a 20% year-over-year growth, with surgical revenue growing by 21% [3][6] - For the full year 2025, total revenue was $764 million, a $153 million increase year-over-year, equating to a 25% growth [4][16] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a margin of 16% [15][22] - Full year Adjusted EBITDA was $93 million, approximately 12% of sales, marking a significant improvement of $63 million year-over-year [17][22] Business Line Data and Key Metrics Changes - Surgical revenue for Q4 was $190 million, while EOS revenue was $23 million, with EOS revenue increasing by 14% year-over-year [6][8] - For the full year, surgical revenue was $687 million, up 26% compared to 2024, driven by a 22% increase in procedural volume [16][17] - EOS revenue for the full year was $77 million, up 15% year-over-year [16] Market Data and Key Metrics Changes - U.S. revenue per case increased by 1.4%, with lateral and cervical cases both up by 6% [7] - Same-store sales in the U.S. grew by 20% year-over-year, indicating strong growth in established territories [8] Company Strategy and Development Direction - The company is focused on creating clinical distinction through proceduralization, particularly in the lateral space, which is seen as a growth engine [24][26] - ATEC aims to expand its market share in spine surgery, particularly in lateral and deformity segments, leveraging its unique procedural ecosystem [26][28] - The company has signed an exclusive distribution partnership with Theradaptive, aiming to introduce a new bone morphogenetic protein (BMP) product to the market [32][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of top-line growth, driven by increasing surgeon adoption and procedural volume [8][19] - The outlook for 2026 anticipates revenue growth of 17% to approximately $890 million, with Adjusted EBITDA guidance increased to $134 million [19][22] - Management emphasized the importance of building a strong foundation for long-term profitable growth through infrastructure investments and expanding the sales force [33][34] Other Important Information - The company ended Q4 with $161 million in cash and had access to an additional $60 million in undrawn credit, totaling $221 million in available cash [18] - Free cash flow for Q4 was $8 million, marking the first full year of positive free cash flow for the company [18][19] Q&A Session Summary Question: Clarification on Q4 results and 2026 guidance - Analyst inquired about the market reaction to the earnings report and sought confirmation on revenue and EBITDA figures [38] - Management confirmed the accuracy of the reported figures and provided insights on expected seasonal revenue patterns for 2026 [41][42] Question: Attracting sales talent - Analyst asked about the company's ability to attract sales personnel and any notable strengths in specific territories [46] - Management responded that there is strong demand for the company's portfolio, indicating a favorable hiring environment [47]

Financial Data and Key Metrics Changes - Q4 2025 revenue reached $213 million, representing a 20% year-over-year growth and a $36 million increase [3][6] - Full year 2025 revenue totaled $764 million, a $153 million increase year-over-year, equating to a 25% growth [4][16] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a margin of 16% [15][22] - Full year Adjusted EBITDA was $93 million, approximately 12% of sales, marking a $63 million improvement year-over-year [17][22] Business Line Data and Key Metrics Changes - Surgical revenue in Q4 was $190 million, up 21% year-over-year, while EOS revenue was $23 million, up 14% [6][7] - For the full year, surgical revenue was $687 million, a 26% increase, driven by a 22% growth in procedural volume [16][17] - EOS revenue for the full year was $77 million, reflecting a 15% year-over-year growth [16] Market Data and Key Metrics Changes - U.S. revenue per case increased by 1.4%, with lateral and cervical procedures both up 6% [6][7] - Same-store sales in the U.S. grew 20% year-over-year, indicating strong growth in established territories [7] - International business presented a 120 basis point headwind due to lower average revenue per case [7] Company Strategy and Development Direction - The company is focused on creating clinical distinction through proceduralization, particularly in lateral surgery, which is seen as a growth engine [24][26] - ATEC is expanding its sales force and enhancing its product offerings, including the introduction of advanced technologies like Valence and EOS Insight [25][28] - The company aims to leverage its unique procedural ecosystem to capture a larger market share in both established and untapped markets [26][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of top-line growth, driven by increasing surgeon adoption and procedural volume [7][19] - The outlook for 2026 anticipates a revenue growth of 17% to approximately $890 million, with an Adjusted EBITDA guidance of $134 million [19][22] - The company is positioned for long-term profitable growth, emphasizing the importance of innovation and operational discipline [34] Other Important Information - The company ended Q4 with $161 million in cash and had access to an additional $60 million in undrawn credit [18] - Positive free cash flow of $8 million in Q4 marked the first full year of positive free cash flow for the company [18][19] Q&A Session Summary Question: Clarification on Q4 results and 2026 guidance - The revenue and EBITDA figures for Q4 were in line with expectations, with EBITDA exceeding consensus by 10% [37][39] Question: Seasonal patterns for 2026 - The company expects increased seasonality in Q2 and Q3, with Q1 revenue anticipated to be around 22.1% of total sales [40][41] Question: Attracting sales talent - The company is experiencing strong demand for its portfolio, indicating it remains a preferred destination for sales talent [46]

Summary of Alphatec Conference Call Company Overview - **Company**: Alphatec Spine - **Industry**: Medical Supplies and Devices, specifically focused on spinal surgery Key Points and Arguments Growth and Financial Performance - Alphatec aims for long-term differentiated growth, with a strong track record of execution and significant growth opportunities in the spine market [2][3] - The company finished 2025 with $764 million in revenue, reflecting a 25% growth, and expects to reach $890 million in revenue by 2026, representing a 17% growth [4][6] - Adjusted EBITDA for 2025 was projected at $91 million (12% of revenue), with expectations of $130 million (15% margin) by 2026 [4][6] - The company has committed to becoming a $1 billion revenue company by 2027, with $180 million in Adjusted EBITDA [5] Market Position and Strategy - Alphatec is now the third largest U.S. market share holder in the spine market, with less than 10% market share across the top 10 U.S. markets, indicating significant growth potential [5][24] - The company has focused on creating clinical distinction to compel surgeon adoption, achieving over 20% growth in surgeon adoption this year [7][8] - The strategy includes proceduralization, which emphasizes the assembly of goods for spine surgery rather than selling individual parts [3][11] Innovations and Technology - Alphatec has made significant investments in informatics and procedural tools, including the acquisition of EOS, a full-body imaging system, and the development of SafeOp, a neurophysiology tool [19][13] - The company is focused on integrating informatics into surgical workflows to improve decision-making and outcomes, with plans to launch Valence, a navigation and robotic tool, in 2026 [14][15][19] - The informatics play is seen as a key driver of long-term value, with a focus on capturing data to enhance surgical decision-making [24][20] Market Dynamics and Competition - The company views recent disruptions in the spine market, such as spin-offs from larger med tech companies, as potential tailwinds for growth [40][41] - Alphatec believes its commitment to neurophysiology and sophisticated surgical tools provides a competitive advantage over fast-following competitors [44][46] Future Outlook - The company anticipates continued strong growth driven by surgical volume and adoption, with a target of $100 million in EOS revenue by 2027 [32][25] - Seasonality effects are expected to influence revenue patterns, particularly with the growing presence in pediatric deformity [31][35] - Alphatec is focused on maintaining profitability while investing in R&D and sales channels to support growth [50][51] Conclusion - The financial outlook for Alphatec is positive, with a commitment to achieving $890 million in revenue and $130 million in Adjusted EBITDA by 2026, alongside a focus on innovation and market expansion [29][50]

Summary of Conference Call Company and Industry - **Company**: Alphatec - **Industry**: Medical Technology, specifically Spine Surgery Key Points and Arguments Lateral Performance and Market Opportunity - Alphatec's lateral performance in Q3 is described as outstanding, indicating strong execution in this segment of the spine market [3][4] - The company believes it is in the early stages of lateral market penetration, with significant opportunities for improvement and clinical experience enhancement [3][5] - The lateral market is estimated to be around $1 billion, with an additional $2 billion potential from traditional posterior approach surgeries that could adopt lateral techniques [6] Technological Integration and Innovation - The integration of navigation robotics and 3D-printed implants is expected to enhance procedural precision and reduce radiation exposure, which is a concern for surgeons [4][5][29] - Alphatec is focusing on improving the clinical experience through better technology integration, which is seen as a catalyst for growth [4][11] Growth Metrics and Projections - The company has been growing at a rate of 8-9 times the market growth, with a projected growth of approximately $130 million in 2023 and nearly $150 million in 2024 [13][16] - A net growth rate of 20% in new surgeons has been reported, indicating strong adoption of Alphatec's procedures [14][15] Market Dynamics and Competitive Landscape - The company is benefiting from disruptions in the market, particularly from competitors like GMED, NuVasive, and Stryker, which may be losing focus [18][22] - Alphatec's sales force is currently one of the smaller ones in the industry, indicating room for growth and expansion [24][26] Future Growth Strategies - The company plans to expand its sales force and enhance its product offerings, particularly in deformity surgery and cervical procedures [24][39] - The integration of informatics tools is expected to provide surgeons with better decision-making capabilities, which is seen as a significant opportunity for growth [40][41] Financial Management and Investment - Alphatec is focused on self-funding its growth through profitability, with a long-term plan that includes a ratio of $0.75 investment in sets and inventory for every dollar of revenue growth [37][38] - The company is confident in its capital allocation strategy, which aims to balance investment in growth with maintaining healthy margins [36] Challenges and Considerations - There is a recognition that the market may eventually slow down, and the company is preparing for this by ensuring it has a robust operational strategy [10][16] - The need for continuous innovation and adaptation to market demands is emphasized, particularly in the context of evolving surgical techniques and technologies [40][42] Other Important Content - The discussion highlights the importance of alignment and bone mineral density in spine surgery, with Alphatec's recent clearance for BMD assessment by level being a unique offering [41][42] - The company is in the early stages of expanding its presence in key geographic markets, with a focus on long-term commitments to growth [21][22]

Financial Data and Key Metrics Changes - Total revenue for the third quarter was $197 million, representing a 30% increase year-over-year and a sequential increase of $11 million from the previous quarter [5][14] - Adjusted EBITDA reached $26 million, or 13% of revenue, marking an improvement of 840 basis points compared to the prior year [4][11] - Free cash flow was reported at $5 million, with total cash and available cash amounting to $260 million [12][14] Business Line Data and Key Metrics Changes - Surgical revenue was $177 million, up 31% year-over-year and 5% sequentially, driven by a procedural volume growth of 28% [5][8] - EOS revenue increased to $20 million, a 29% rise compared to the prior year, with strong demand in the U.S. market [8][9] - Same-store sales in the U.S. grew 30% year-over-year, indicating strong performance in established territories [8][9] Market Data and Key Metrics Changes - The company reported a 30% growth in same-store sales, reflecting strong demand in existing markets [8] - The increase in new surgeon users by 26% in the third quarter indicates a growing adoption of the company's products [5][6] Company Strategy and Development Direction - The company remains 100% spine-focused, emphasizing proceduralization and expanding its product offerings in lateral, cervical, and deformity markets [3][19] - The strategic focus includes leveraging technology integration to enhance surgical outcomes and democratize surgical techniques [20][25] - The company is positioned to meet its long-range plan commitments, aiming for $1 billion in revenue by 2027 [17][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver durable revenue growth and strong profitability improvements [11][17] - The company anticipates raising its full-year revenue guidance by $18 million to $760 million, driven by overperformance in case volume [14][15] - Management highlighted the importance of surgeon adoption and the long-term potential of the spine market, indicating a positive outlook for future growth [18][67] Other Important Information - The company has seen a significant improvement in its operating margin, with a 1,100 basis points expansion year-over-year [10][11] - The trailing 12-month adjusted EBITDA now stands at $81 million, reflecting the company's ability to generate cash flow [11][12] Q&A Session Summary Question: Cash flow expectations for next year - Management expects free cash flow for next year to be around $20 million, aligning with revenue growth and EBITDA drop-through [32][33] Question: Update on long-range plan - An update to the long-range plan is anticipated towards the end of next year as the company progresses through 2026 [34] Question: Competitive landscape and consolidation - The company welcomes market disruption and believes it can capitalize on the current dynamics in the spine market [37][39] Question: Role of Valence in lateral space - Valence is expected to enhance efficiency and democratize surgical techniques, benefiting both experienced and new users [40][44] Question: Health of the spine market and competitive dynamics - The spine market remains healthy, with the company taking share from multiple competitors, reflecting decisions made 18 to 24 months ago [48][50] Question: Balancing growth and profitability - The company aims to balance growth and profitability by investing in innovation while leveraging existing infrastructure [52][54] Question: Timing for deformity portfolio contributions - The company is in the early stages of influencing the deformity market, with several products in the design phase and a focus on expanding EOS availability [73][75]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $177 million, representing a 28% increase year-over-year and a 17% sequential increase [13] - Full year 2024 total revenue reached $612 million, up 27% compared to the prior year [24] - Adjusted EBITDA for Q4 was $21 million, equating to a 12% margin, with over 1,000 basis points of improvement year-over-year [20] - Non-GAAP gross margin was 70%, flat compared to the previous year [16] - Free cash flow generated in Q4 was $9 million, marking the first cash flow since the transformation [23] Business Line Data and Key Metrics Changes - Surgical revenue for Q4 was $157 million, up 28% year-over-year, with procedural volume growth of 19% and average revenue per procedure growth of 7% [13][14] - EOS revenue for Q4 was $20 million, up 32% year-over-year, driven by robust demand and record order volume [15] - Surgical revenue for the full year was $545 million, a 29% increase compared to 2023 [24] Market Data and Key Metrics Changes - The company holds an 8% market share in the spine market, indicating significant growth potential [6] - Surgeon adoption grew by 19% on a five-year CAGR, with procedural volume growth at 25% [7] Company Strategy and Development Direction - The company aims to revolutionize spine surgery by improving procedural durability and predictability through informatics [40][41] - The focus is on leveraging unique technologies and clinical distinctions to capture market share in a disrupted environment [56][58] - Plans for 2025 include a revenue growth target of approximately $732 million, with surgical revenue growth of 21% [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on financial commitments and translate revenue growth into profit and cash flow [21][34] - The company is optimistic about the growth potential in Japan, having conducted its first surgeries there [11][125] - Management highlighted the importance of operational discipline and efficiency improvements in driving profitability [19][78] Other Important Information - The company is positioned as the largest pure-play spine company, focusing exclusively on spine-related products and technologies [45] - The introduction of EOS Insight software is expected to enhance growth and adoption rates [102][106] Q&A Session Summary Question: Assurance on spending in 2025 amidst industry disruption - Management indicated that previous investments have been made and there are no plans for outsized expenses that could undermine financial goals [50] Question: Potential benefits from a competitor's sale of its spinal implants business - Management sees disruption as an opportunity and believes their informatics platform positions them favorably to attract talent from competitors [56][58] Question: International plans for 2025, particularly in Japan - Management emphasized a disciplined approach to entering the Japanese market, focusing on long-term growth rather than immediate gains [62] Question: Growth potential of PTP and LTP offerings - Management believes they are in the early stages of growth for PTP and LTP, with significant market opportunities ahead [70][72] Question: Efficiencies targeted in SG&A - Management discussed deliberate organizational reductions and improved operational efficiency, which are expected to continue benefiting the bottom line in 2025 [76][78] Question: Strategy for share capture and regional field team upgrades - Management noted ongoing improvements in sales force effectiveness and the need for further expansion in underrepresented geographies [83][86] Question: Competitive positioning with upcoming robotic technology - Management views robotics as part of a broader solution to surgical challenges, emphasizing the importance of systemic variables in surgical outcomes [91][92] Question: Opportunities in pediatric surgery - Management acknowledged being underpenetrated in pediatric surgery but sees potential for growth leveraging existing EOS technology [100][118] Question: Growth expectations for EOS - Management anticipates continued growth for EOS, with expectations for increased adoption and monetization through implant pull-through [102][106]